标题
MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21
作者
关键词
-
出版物
Science Translational Medicine
Volume 11, Issue 505, Pages eaav7171
出版商
American Association for the Advancement of Science (AAAS)
发表日期
2019-08-15
DOI
10.1126/scitranslmed.aav7171
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib
- (2019) Melania Poratti et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- CDK4/6 Inhibitors in Combination With Hormone Therapy for HR + /HER2 − Advanced Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
- (2018) Yunfu Deng et al. Clinical Breast Cancer
- Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells
- (2018) Priyank Patel et al. MOLECULAR CANCER RESEARCH
- In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms
- (2018) Jessica L.F. Teh et al. Cancer Discovery
- A Preexisting Rare PIK3CA E545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling
- (2018) Gabriele Romano et al. Cancer Discovery
- Preclinical evaluation of ribociclib and its synergistic effect in combination with alpelisib in non-keratinizing nasopharyngeal carcinoma
- (2018) Chi-Hang Wong et al. Scientific Reports
- New Insights into Protein Kinase B/Akt Signaling: Role of Localized Akt Activation and Compartment-Specific Target Proteins for the Cellular Radiation Response
- (2018) Klaudia Szymonowicz et al. Cancers
- Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
- (2017) Audrey Laroche-Clary et al. Journal of Hematology & Oncology
- RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1
- (2017) S-H Chen et al. ONCOGENE
- MDM2 Antagonists Counteract Drug-Induced DNA Damage
- (2017) Anna E. Vilgelm et al. EBioMedicine
- Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
- (2016) Shom Goel et al. CANCER CELL
- Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
- (2016) Maria Teresa Herrera-Abreu et al. CANCER RESEARCH
- A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
- (2016) J. R. Infante et al. CLINICAL CANCER RESEARCH
- Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
- (2016) P. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
- (2016) A. Patnaik et al. Cancer Discovery
- Implications of Genetic and Epigenetic Alterations of CDKN2A (p16 INK4a ) in Cancer
- (2016) Ran Zhao et al. EBioMedicine
- Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6
- (2015) E. K. Ziemke et al. CLINICAL CANCER RESEARCH
- Treatment of NRAS-Mutant Melanoma
- (2015) Douglas B. Johnson et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment
- (2015) Anna E. Vilgelm et al. JNCI-Journal of the National Cancer Institute
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- The PI3K-PKB/Akt Pathway
- (2015) Brian A. Hemmings et al. Cold Spring Harbor Perspectives in Biology
- Targeting CDK4 and CDK6: From Discovery to Therapy
- (2015) C. J. Sherr et al. Cancer Discovery
- Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment
- (2015) Anna E. Vilgelm et al. JNCI-Journal of the National Cancer Institute
- Combined therapies that induce senescence and stabilize p53 block melanoma growth and prompt antitumor immune responses
- (2015) Anna Vilgelm et al. OncoImmunology
- CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
- (2014) Sadhna R. Vora et al. CANCER CELL
- Mdm2 and Aurora Kinase A Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells
- (2014) A. E. Vilgelm et al. CANCER RESEARCH
- The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
- (2014) V. Yadav et al. MOLECULAR CANCER THERAPEUTICS
- Loss ofCDKN2Aexpression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines
- (2014) Richard J. Young et al. Pigment Cell & Melanoma Research
- Cyclin-dependent kinases as therapeutic targets in melanoma
- (2014) David M. Miller et al. Pigment Cell & Melanoma Research
- Cyclin-dependent kinases
- (2014) Marcos Malumbres GENOME BIOLOGY
- Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP
- (2013) Min Lu et al. CANCER CELL
- The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
- (2013) K. E. Sheppard et al. CLINICAL CANCER RESEARCH
- Preparation of (−)-Nutlin-3 Using Enantioselective Organocatalysis at Decagram Scale
- (2013) Tyler A. Davis et al. JOURNAL OF ORGANIC CHEMISTRY
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
- (2012) Lawrence N Kwong et al. NATURE MEDICINE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but not for liver regeneration
- (2012) M. K. Diril et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MAP Kinase Pathways
- (2012) D. K. Morrison Cold Spring Harbor Perspectives in Biology
- A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells
- (2011) Lars Anders et al. CANCER CELL
- Multiple faces of FoxM1 transcription factor
- (2011) Tanya V. Kalin et al. CELL CYCLE
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
- (2011) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- WIPI1 Coordinates Melanogenic Gene Transcription and Melanosome Formation via TORC1 Inhibition
- (2011) Hsiang Ho et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Four faces of cellular senescence
- (2011) Francis Rodier et al. JOURNAL OF CELL BIOLOGY
- p53 Rescue through HDM2 Antagonism Suppresses Melanoma Growth and Potentiates MEK Inhibition
- (2011) Zhenyu Ji et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- E2F1-dependent oncogenic addiction of melanoma cells to MDM2
- (2011) M Verhaegen et al. ONCOGENE
- mTOR Signaling
- (2011) M. Laplante et al. Cold Spring Harbor Perspectives in Biology
- Transcriptional role of cyclin D1 in development revealed by a genetic–proteomic screen
- (2010) Frédéric Bienvenu et al. NATURE
- Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
- (2010) J L Dean et al. ONCOGENE
- Cdk2 and Cdk4 Activities Are Dispensable for Tumorigenesis Caused by the Loss of p53
- (2009) V. C. Padmakumar et al. MOLECULAR AND CELLULAR BIOLOGY
- Cyclin-dependent kinases: a family portrait
- (2009) Marcos Malumbres et al. NATURE CELL BIOLOGY
- Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
- (2009) Da Wei Huang et al. Nature Protocols
- p21 Inhibits Cdk1 in the Absence of Cdk2 to Maintain the G1/S Phase DNA Damage Checkpoint
- (2007) Ande Satyanarayana et al. MOLECULAR BIOLOGY OF THE CELL
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started